Drugs / ATN-161
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00352313 | May 2006 → Jan 2007 | central nervous system neoplasm | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00131651 | Aug 2005 → ? | renal cell carcinoma | Attenuon | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATN-161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00131651 ↗ |
| Known as | Ac-phscn-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297456 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297456 ↗ |
| Route | Intravenous | “by short (10 minute) IV infusion” NCT00131651 ↗ |